Background and Purpose-Aneurysmal subarachnoid hemorrhage (SAH) is a cerebrovascular disease with a high mortality rate and severe disability. Longitudinal studies investigating health-economic costs in SAH are scare and only one of them analyzed cost-driving factors. The objective was to evaluate first-year costs in German patients with aneurysmal SAH and to identify independent determinants of costs.
neurosurgical center with a well-defined catchment area of approximately 500 000 people. The overall amount of 143 incident cases with ruptured and unruptured cerebral aneurysms treated between January 2004 and December 2005 was screened for the participation in the study. All patients underwent either endovascular coiling or surgical clipping in accordance with the results of the ISAT study. 1 The inclusion criteria were: (1) definite diagnosis of SAH proven by cranial CT, cranial MRI, or lumbar puncture; (2) aneurysmal cause of SAH as demonstrated by intra-arterial or by cranial CT angiography; and (3) patients who could give informed consent for participation in the study. Patients with incidental aneurysms were excluded. According to the inclusion criteria, 113 patients with aneurysmal SAH were eligible for the study. Of these, 12 were excluded because their clinical or health-economic data were incomplete. There were no significant differences in age, gender, or disease severity between dropouts and remaining 101 study completers. The study protocol was approved by the local ethics committee of the University of Bonn. Informed consent was obtained from all study participants or their legal caregivers.
Clinical Evaluation
A complete medical and neurological examination was performed by a specialist in cerebrovascular diseases (study investigator) in each patient at admission at the time of discharge and at 6-and 12-month follow-up time points. Clinical status at admission was evaluated using the World Federation of Neurological Surgeons scale 13 and the Hunt and Hess scale (H&H). 14 The following clinical parameters were evaluated at discharge as well as at 6-and 12-month follow-up time points: (1) functional status and disability (modified Rankin Scale and Barthel Index). The Barthel Index (BI) measures the disability on a scale from 0 (totally dependent and bedridden state) to 100 (fully independent). 15 The modified Rankin Scale (mRS) is a measure of functional status ranging from 0 (no symptoms) to 5 (severe impairment). Scores from 0 to 2 on the mRS were considered as independency in activities of daily living and scores from 3 to 5 were classified as moderate to severe disability 16 ; (2) Depression (Beck Depression Inventory) 17 and cognitive impairment (MiniMental State Examination) 18 ; and (3) Health-related quality of life. The EuroQol consists of a questionnaire describing 5 dimensions of the health-related quality of life ("mobility," "self-care," "usual activities," "pain/discomfort," "anxiety/depression") and a visual analog scale scoring from 0 to 100 with 0 representing the worst and 100 the best imaginable health state. 19 
Health-Economic Evaluation
Health-economic data were collected through a standardized questionnaire administered at 6-and 12-month follow-up. Each questionnaire covered the resource use of the preceding 6 months, respectively. The health-economic questionnaire used in this study was developed and applied in previous cost of illness studies in neurological diseases, including cerebrovascular diseases. 2,20 -22 Costs were calculated for the 12-month period from a societal perspective and adjusted to 2009 Euros (€) using the Consumer Price Index. 5 Only SAH-related costs were included in the cost calculation. The following cost categories were examined in the analysis.
Direct Costs
The expenditures of the health insurance company and the out-ofpocket cost of patients and their families were categorized as direct costs.
Health Insurance Costs
Costs for inpatient care (hospitalization and rehabilitation) were calculated using the official reimbursement catalogue of the German Diagnosis-Related Groups (2005). 23 Costs for outpatient care were obtained by multiplying the number of outpatient visits by the provider-specific charge according to the official German doctor's fee scale ("Einheitlicher Bewertungsmaßstab"). 24 The number of outpatient diagnostic procedures and nonmedical ancillary therapies (physiotherapy, speech therapy, and occupational therapy) was multiplied by the German charge ("Einheitlicher Bewertungsmaßstab") to calculate costs for diagnostics and ancillary treatment. Drug costs were calculated using the official German price list of drugs ("Rote Liste"). 25 Only SAH-related drug costs were included in the analysis (eg, antihypertensive drugs, antiepileptic drugs for treatment of epileptic seizures after SAH).
Copayments by patients were subtracted from the official outpatient tariffs and drug prices and added to the out-of-pocket costs.
Formal care or professional home care was calculated according to the regulations for financial support in case of disability defined by the Federal Ministry for Health and Social Security. According to these regulations, financial support provided by health insurance for professional nursing care depends on the disability and amounts to €384 (first level), €921 (second level), and €1432 (third level) per month. 26 Patients and their caregivers reported the level of financial support related to SAH.
Out-of-Pocket Costs
Out-of-pocket costs consisted of costs for informal care and copayments for treatments and drugs. A replacement approach was used to calculate the costs for informal care or home care provided by family and friends. According to this approach, costs were calculated similarly to costs for formal care considering the three levels of financial support described previously.
Copayments by patients and families for treatments and drugs were calculated based on patient statements. Income losses caused by SAH-related early retirement or temporary sickness were not calculated separately to avoid double counting with the indirect costs. As such, they were treated as productivity losses (see subsequently).
Indirect Costs
Indirect costs, or productivity losses, due to premature retirement were calculated using the human capital approach. The mean gross income given by Federal Statistics 5 was divided by 365 calendar days and then multiplied by the calendar days in the remaining study period before the 65th birthday (official retirement age in Germany). For productivity losses due to sick leave, the mean gross income was divided by 365 calendar days and then multiplied by the days of sick leave. In case of early mortality, productivity losses were calculated similar to premature retirement. The mean gross income was divided by 365 calender days and then multiplied by number of days in the remaining study period to official retirement age.
Statistical Analysis
Statistical analysis was performed using STATA 9.2 (StataCorp, Stata Statistical Software, Release 9.2 [2005] ; College Station, Texas). Cost variables are in most cases right-skewed and, therefore, traditional statistical methods are inappropriate for analyzing differences in mean costs. 27 Potential skewness in the cost data can be accommodated by using the 95% CI calculated by a nonparametric bootstrap algorithm. 28 In our analysis, a bias-corrected and accelerated bootstrapping method with Bϭ2000 bootstrap replications was used to calculate 95% CIs. 28 Differences in mean costs between groups were tested using a bootstrap t test. 27 Statistical inference was based on a probability value Ͻ0.05. Multiple regression analysis with SEs estimated using the bootstrapping technique was performed to identify cost-driving factors. Clinical variables used as potential cost-driving factors in the multivariate analyses were specified based on the results of the univariate analysis and data of previous studies. 1, 7, 10, 12, 29 The R 2 method was applied to calculate the fraction of variability explained. 30 
Results

Demographics and Clinical Features
Among 101 patients with aneurysmal SAH who participated in the study, 29.7% (nϭ29) were male and 70.3% (nϭ72) were female. The mean age of study participants was 51.7Ϯ13.0 years. Demographic, social, and clinical parameters stratified by age groups are shown in Table 1. A total of 19 patients died during the observation period. At the time of discharge, 42.7% (nϭ35) of survivals had moderate or severe disability (BI Յ70). The functional status of patients measured using BI improved at 6-and 12-month follow-up (21.9%, nϭ18 and 17.0%, nϭ14 of patients with BI Յ70, PϽ0.01). The proportion of patients with depressive symptoms (Beck Depression Inventory Ͼ9) increased from 24.8% (nϭ25) at discharge to 57.4% (nϭ58) at the 12-month follow-up point (PϽ0.001).
Cost Data
The total costs were calculated at €38 300 (95% CI, 34 490 to 43 100) per patient per year. Table 2 shows the components of total costs. Total costs stratified by H&H at admission are depicted in the Figure. They were increased in patients with H&H 3 to 5 by factor 1.4 as compared with patients with H&H 1 to 2 (Pϭ0.04).
Direct costs accounted for 58.7% of total costs and were mainly paid by the health insurance company (92.0%). Inpatient costs were the main cost component of direct and total cost in the first year after aneurysmal SAH (42.8% of total costs). All patients with SAH were hospitalized and 46.5% (nϭ47) of them were discharged to the rehabilitation clinics. The mean length of stay in the hospital was 14.9Ϯ19.1 days. Outpatient care received 91.1% (nϭ92) of patients. In 78.3% of patients (nϭ72), follow-up with neuroimaging was performed in an outpatient setting. In 44.4% (nϭ32) of these patients, neuroimaging was performed more than once. Angiography was the most expensive imaging procedure and accounted for 59.3% of imaging costs.
Drug costs made up to 4.2% of direct costs (Table 2) . Patients with SAH received informal care more often than formal care and costs of informal care exceeded costs of formal care by a factor of 1.6. Indirect costs caused by SAH-related premature retirement or sick leave amounted to €15 840 (95% CI, 13 150 to 18 820) and accounted for 41.4% of total costs.
Cost-Driving Factors
The results of bivariate analyses of determinants of total costs are shown in Table 3 . The following clinical variables were associated with increased total costs: younger age, increased disease severity at admission (H&H 3 to 5), and worse functional outcome after 12 months (BI, mRS). These variables were used in the multivariate analysis (Table 4) . mRS was excluded from the multivariate analysis due to collinearity with the BI. The independent determinants of increasing costs identified in the multiple regression analysis were younger age and worse functional outcome at 12-month follow-up (BI). Together, these were able to explain 44.0% (adjusted R 2 ) of the variance in total costs.
Discussion
In this longitudinal study, the socioeconomic burden of SAH was evaluated in a cohort of German patients treated in a large neurosurgical/neuroradiological center with a well-defined catchment area of approximately half a million people. Cost data were calculated on the level of individual patients. This approach, also known as the "bottom-up" approach, allows obtaining more precise data than a "top-down" approach, which calculates costs by splitting down highly aggregated statistical data such as reports of national statistics. The total costs in the first year after aneurysmal SAH were €38 300 per patient and consisted largely of direct costs (58.7% or €22 470). Roos et al calculated similar first-year 12 According to data of Rivero-Arias et al, direct costs of aneurysmal SAH in the United Kingdom were €33 290 per patient (2009 price level) during the first 24 months after SAH. 1 However, authors did not include primary care and informal care in the cost calculation and underestimated direct costs. To the best of our knowledge, there are no published studies investigating first-year costs after aneurysmal SAH in other countries. Considering the incidence of SAH in Germany and annual costs per patient calculated in our study, the total annual costs of incident SAH in Germany can be estimated at approximately €437 million.
A few studies focused on inpatient costs of aneurysmal SAH. The highest inpatient costs were calculated in the United States (US $41 905 per patient, or €28 900, 2009 price level). 10 Inpatient costs of aneurysmal SAH in our study were lower (€16 390) and were comparable to costs calculated by Venketasubramanian et al in Singapore (€16 030, 2009 price level). 7 In Australia, inpatient costs were US $25 880 (€16 590, 2009 price level). 11 Generally, inpatient costs were one of the main cost components. Depending on the study, they accounted for 75% to 92% of first-year direct costs after SAH. 1, 12 Similarly, inpatient costs accounted for 73% of first-year direct costs in our study.
Corresponding to the results of other studies of acute cerebrovascular diseases, first-year outpatient costs of SAH in our study were much lower than inpatient costs. 2, 6, 12 Kolominski-Rabas et al showed that the ratio outpatient cost/inpatient costs is increasing in the subsequent years after an acute cerebrovascular event. 6 This pattern can be expected for the long-term costs of SAH; however, they were beyond the scope of our study. Neuroimaging was one of the main components of outpatient costs in the first year after SAH. Among other imaging procedures, angiography was the most costly (59% of imaging costs). This corresponds well with the results of the study by Roos et al. 12 In contrast to chronic neurological diseases, costs of medication in acute cerebrovascular diseases are usually low. 2, 8, 12 Costs of antihypertensive medication and drugs used in the treatment of complications of SAH in our study were relatively low in comparison to other cost components. Similar to the results of another European study, they accounted for 4% of direct costs in SAH. 12 Only one previous study by Rivero-Arias et al used multivariate analysis to identify cost-driving factors in SAH. 1 In contrast to the results of our study, increasing age was associated with higher total costs. As mentioned previously, authors did not include primary care and informal care in cost calculation and this interfered with the results of the multivariate analysis. Costs of informal care in our study were higher in younger patients, because they were preferably cared for by their family members. This could explain the difference in the results of the multivariate analysis between the study by Rivero-Arias et al and our study. 1 Besides younger age, a worse functional outcome at 12-month follow-up was identified as a cost-driving factor in our analysis. Unfortunately, clinical outcome was not included in the multivariate analysis of Rivero-Arias et al. 1 These authors identified disease severity at admission measured in World Federation of Neurological Surgeons grades as another costdriving factor in SAH. In our study, clinical outcome measured by the BI was a stronger predictor of increasing costs than disease severity at admission. *Ninety-five percent bootstrap CI calculated using the bias-corrected and accelerated method. Figure.
Hunt and Hess
Costs of aneurysmal SAH stratified by H&H grades at admission.
The cost-driving factors identified in our study should be considered in healthcare programs in SAH. The patients of working age should be provided with advanced rehabilitation programs aimed on return to working life. The healthcare programs should provide adequate investments in the acute phase of SAH treatment to improve functional outcome. Our previous analysis showed that cost-intensive specialized treatment approaches in acute stroke care such as stroke unit treatment are associated with better functional outcome and reduce postacute costs. 8 Increased investments in the early disease pay off in reduced costs of rehabilitation and reduced indirect costs.
Despite a careful study design, our study carries a few limitations: (1) it is a single-center study and, therefore, extrapolation of data on the national level is limited. However, SAH treatment in Germany is carried out in specialized neurosurgical centers, using similar standardized procedures, and costs calculated in our study center should provide an adequate approximation of per-patient costs in Germany. Future multicenter studies will provide more precise estimations; (2) the "bottomup" approach relies on data collected directly from individuals. We cannot exclude that some details were not reported by patients resulting in an underestimation or bias toward costs; (3) informed consent could not be obtained from patients with aphasia or impaired consciousness. The exclusion of these patients with severe SAHs may lead to an underestimation of costs; and (4) finally, residual confounding by unmeasured variables in the multivariate analyses cannot be excluded.
In conclusion, aneurysmal SAH is a cerebrovascular disease, which affects predominantly young people and results in a considerable economic burden for the society, individual patients, and their families. Unfortunately, independent determinants of SAH-related costs were evaluated only in one previous study. Our study identified younger age and worse long-term functional outcome as independent factors increasing socioeconomic costs of aneurysmal SAH. Further health-economic studies investigating cost-drivers of SAH in different countries are needed to promote the development of healthcare programs aimed at reduction the economic burden of aneurysmal SAH on society and patients. Meta-analysis of these studies will show how different healthcare systems influence the components of cost in SAH and which patterns of health care in SAH should be integrated in other countries to optimize costs. 
